COMPOSITION:

Each LuciGil tablet contains: 44.2mg Gilteritinib Fumarate equivalent to Gilteritinib ......… 40mg

INDICATION:  

LuciGil is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

DOSAGE AND USE:

The recommended starting dose of LuciGil is 120 mg orally once daily with or without food. In the absence of disease progression or unacceptable toxicity, treatment for a minimum of 6 months is recommended to allow time for a clinical response.

Tablet should be swallowed whole & not chewed or crushed.

STORAGE:

in a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of the reach of Children. Do not administered LuciGil in Pregnancy and Lactation patient treatment.